Arcus Biosciences Inc (RCUS) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Arcus Biosciences Inc (RCUS) following the 2026 Q2 hedge fund 13F filings?

As of today, RCUS has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), RCUS gained -4.4% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Arcus Biosciences Inc (RCUS)

206 + Investors. Track Smart Money conviction in RCUS. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — RCUS

Based on 208 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added RCUS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

208 hedge funds hold RCUS right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +14% more funds vs a year ago

fund count last 6Q

+26 new funds entered over the past year (+14% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟡

Slight buying edge — 57% buying

122 buying93 selling

Last quarter: 122 funds bought or added vs 93 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-10 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 25 → 31 → 49 → 39. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔒

56% of holders stayed for 2+ years

■ 56% conviction (2yr+) ■ 20% medium ■ 24% new

117 out of 208 hedge funds have held RCUS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

🚀

Acceleration phase — new buyers rushing in

32 → 25 → 31 → 49 → 39 new funds/Q

New funds entering each quarter: 25 → 31 → 49 → 39. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🏛️

Veteran-anchored — 66% veterans vs 25% newcomers

■ 66% veterans ■ 8% 1-2yr ■ 25% new

Entry-cohort mix of 220 holders: 146 (66%) are 2+ year veterans, 18 entered 1–2 years ago, and 56 (25%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

✅

Strong quality — 37% AUM from major funds

37% from top-100 AUM funds

45 of 207 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

3.9

out of 10

Low Exit Risk

Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	206	204	0.98%
13F Shares	119M	125M	-4.64%
Total Value	$2.57B	$2.98B	-13.81%
New Positions	37	49	-12
Increased Positions	81	96	-15
Closed Positions	35	28	+7
Reduced Positions	56	37	+19
Total Calls	6	10	-40.0%
Total Puts	7	8	-12.5%
PUT/CALL Ratio	1.17	0.8	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

206

204

0.98%

13F Shares

119M

125M

-4.64%

Total Value

$2.57B

$2.98B

-13.81%

New Positions

-12

Increased Positions

-15

Closed Positions

Reduced Positions

+19

Total Calls

-40.0%

Total Puts

-12.5%

PUT/CALL Ratio

1.17

0.8

Neutral

Institutional Holders (2026 Q2)

206 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in RCUS. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 RCUS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Gilead Sciences, INC.	58.76%	31,424,760	$968.8M
2	Parkman Healthcare Partners LLC	2.90%	919,266	$28.3M
3	Montanova Capital, LLC	2.69%	4,776,423	$147.3M
4	DAFNA Capital Management LLC	2.60%	441,829	$13.6M
5	Sectoral Asset Management Inc	2.39%	110,870	$3.4M
6	Decheng Capital LLC	1.96%	464,779	$14.3M
7	Patient Square Capital LP	1.70%	355,800	$11.0M
8	Ikarian Capital, LLC	1.68%	504,559	$15.6M
9	Siren, L.L.C.	1.51%	2,420,430	$74.6M
10	Sofinnova Investments, Inc.	1.51%	945,690	$29.2M
11	Knott David M Jr	1.32%	81,241	$2.5M
12	Soleus Capital Management, L.P.	1.24%	1,168,738	$36.0M
13	Platinum Investment Management Ltd	1.02%	134,217	$4.1M
14	Diadema Partners LP	0.87%	223,810	$6.9M
15	Logos Global Management LP	0.86%	650,000	$20.0M
16	Samlyn Capital, LLC	0.78%	1,547,182	$47.7M
17	Persistent Asset Partners Ltd	0.52%	57,048	$1.8M
18	PDT Partners, LLC	0.52%	323,567	$10.0M
19	Diadema Partners LP	0.48%	124,000	$3.8M
20	Odyssean, LLC	0.43%	85,497	$2.6M
21	PFM Health Sciences, LP	0.40%	152,129	$4.7M
22	Bayforest Capital Ltd	0.36%	12,709	$392K
23	Woodline Partners LP	0.29%	3,007,798	$92.7M
24	Rock Springs Capital Management LP	0.27%	180,000	$5.5M
25	Seelaus Asset Management LLC	0.14%	6,540	$202K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Arcus Biosciences Inc (RCUS)

What does the Smart Money Trend signal show for RCUS?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added RCUS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for RCUS?

Slight buying edge — 57% buying: Last quarter: 122 funds bought or added vs 93 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for RCUS holders?

Strong quality — 37% AUM from major funds: 45 of 207 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held RCUS?

56% of holders stayed for 2+ years: 117 out of 208 hedge funds have held RCUS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Arcus Biosciences Inc (RCUS) following the 2026 Q2 hedge fund 13F filings?

As of today, RCUS has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), RCUS has gained -4.4% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Arcus Biosciences Inc (RCUS)

Smart Money Signals — RCUS

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Steady growth — +14% more funds vs a year ago

Slight buying edge — 57% buying

Fewer new buyers each quarter (-10 vs last Q)

56% of holders stayed for 2+ years

Acceleration phase — new buyers rushing in

Veteran-anchored — 66% veterans vs 25% newcomers

Strong quality — 37% AUM from major funds

Institutional Sentiment Summary — RCUS

Hedge Fund Ownership: RCUS

Market Analysis: RCUS

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: RCUS

Is It Too Late to Buy Arcus Biosciences Inc (RCUS) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: RCUS

Statistics: RCUS

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Arcus Biosciences Inc (RCUS)

Welcome to 13Foresight!